<DOC>
	<DOCNO>NCT01526135</DOCNO>
	<brief_summary>This multicentric randomized phase III trial compare adjuvant chemotherapy gemcitabine versus 5-fluorouracil , leucovorin , irinotecan oxaliplatin ( mFolfirinox ) patient resect pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox Treat Resected Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>STUDY DESIGN/ Evaluation criterion Main criterion : efficacy The main criterion disease-free survival 3 year . Disease-free survival time delay date randomization date 1st cancer-related event local relapse , distant metastasis , second cancer death cause observe . Patients without event time anlaysis censor date last follow-up visit . Locoregional relapse disease relapse occur site primary resection , pancreas associate regional lymph node . Metastatic relapse distant disease recurrence involve possible site relapse ( peritoneal , hepatic , pulmonary , distant lymph node ) . Secondary criterion Overall specific survival Overall survival time delay date randomization patient 's death , irrespective cause . Patients still live time analysis censor date last follow-up visit . Specific survival time delay date randomization patient 's death due treat cancer treatment-related complication . Metastasis-free survival Metastasis-free survival time delay date randomization date 1st distant event occurrence ( peritoneal , hepatic , pulmonary , lymph node ) . Loco-regional event discard patient still live without metastasis time analysis censor date last follow-up examination objectively assess type event . Tolerance Patients evaluable toxicity must receive least one course injection treatment .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>1 . Histologically proven pancreatic ductal adenocarcinoma . Intraductal papillary mucinous tumor pancreas ( IPMT ) invasive component eligible . 2 . Macroscopically complete resection ( R0 R1 resection ) . 3 . Patients age 18 79 year . 4. WHO performance status 01 . 5 . No prior radiotherapy previous chemotherapy . 6 . Full recovery surgery patient able receive chemotherapy : adequate oral nutrition ≥ 1500 calorie per day free significant nausea vomit 7 . Adequate hematologic function ( Absolute neutrophil count ANC ≥ 1,500 cells/mm3 , platelet ≥ 100 000 cells/mm3 hemoglobin ≥ 10 g/L possibly transfusion ) . 8 . Serum total bilirubin ≤ 1.5 time institutional upper limit normal . 9 . Creatinine level &lt; 130 micromol/L ( 14.7 mg / L ) . 10 . Patient childbearing potential ( female patient : study entry menstrual period negative pregnancy test ) must agree use two medically acceptable method contraception ( one patient one partner ) study 4 month last study treatment intake woman 6 month men . 11 . Interval since surgery 21 84 day 12 . Patient information sign informed consent . 13 . Public private health insurance coverage 1 . Other type nonductal tumor pancreas , include endocrine tumor acinar cell adenocarcinoma , cystadenocarcinoma malignant ampulloma . 2 . Metastases ( include ascites malignant pleural effusion ) . 3 . Macroscopic incomplete tumor removal ( R2 resection ) . 4 . CA 199 &gt; 180 U / ml within 21 day registration study . 5 . No heart failure coronary heart disease symptoms 6 . No major comorbidity may preclude delivery treatment active infection ( HIV chronic hepatitis B C ) uncontrolled diabetes . 7 . Preexisting neuropathy , Gilbert 's disease genotype UGT1A1 * 28 / * 28 . 8 . Inflammatory disease colon rectum , occlusion subocclusion intestine severe postoperative uncontrolled diarrhea 9 . Concomitant occurrence another cancer , history cancer except situ carcinoma cervix treat basal cell carcinoma squamous cell carcinoma . 10 . Fructose intolerance . 11 . Persons deprive liberty guardianship . 12 . Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>National multicentric phase III superiority trial</keyword>
</DOC>